ACTRN12611001210965CompletedPhase 2
An open label phase II/III clinical trial of Ranibizumab on the effects and safety for diabetic macular oedema resistant to intravitreal triamcinolone (TAREDS)
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- the University of Sydney
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- All
Inclusion Criteria
- •All patient with diabetic macular oedema resistant to IVTA treatment.
- •IVTA resistance is defined as
- •- An improvement in VA of less than 5 letters
- •- A reduction in central retinal thickness in OCT of less than 100 microns
- •(or less than 20%, whichever is greater) 6 weeks after treatment with IVTA for at least 2 consecutive injections.
Exclusion Criteria
- •- loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration)
- •- no useful vision in fellow eye
- •- cataract surgery or retinal laser within 1st six months of entering the study
- •- uncontrolled systemic disease including blood pressure>180/110
Investigators
Similar Trials
Active, not recruiting
Phase 1
An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancerEUCTR2020-000824-21-FRInstitut Jules Bordet
Active, not recruiting
Phase 1
An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancerHER2 positive breast cancer patients with brain metastasesMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2020-000824-21-BEInstitut Jules Bordet125
Active, not recruiting
Phase 1
A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer - Not availableocally advanced or metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2008-005425-11-ATWyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company230
Active, not recruiting
Phase 1
A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancerocally advanced or metastatic breast cancerMedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005425-11-HUWyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA233
Active, not recruiting
Phase 1
A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancerocally advanced or metastatic breast cancerMedDRA version: 15.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005425-11-DEPuma Biotechnology, Inc233